<DOC>
	<DOC>NCT01728948</DOC>
	<brief_summary>This prospective, single arm, multi-center pilot study includes 120 mRCC patients over 65 years, no prior systemic treatment, determined to be candidates for systemic therapy by the investigator. The treatment with Sorafenib should comply with the recommendations written in the local product information. The primary endpoint is overall survival. The secondary endpoints including other effectiveness points, safety and patients characteristics. With 120 completed patients, if the observed survival rate at 12 months is 60%, the width of a 95% confidence interval will be approximately 18%.</brief_summary>
	<brief_title>Sorafenib in Elderly mRCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients with histologically/cytologically diagnosed metastasis RCC who are candidates for systemic therapy and have decided to accept Sorafenib treatment. &gt;=65 years of age Patients who have signed the informed consent Patients with a life expectancy of â‰¥12 weeks No prior systemic treatment The approved local product label must be followed for the exclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>renal cell carcinoma(RCC)</keyword>
	<keyword>elderly</keyword>
	<keyword>effectiveness</keyword>
	<keyword>safety</keyword>
</DOC>